TERN-601 for Obesity
(FALCON Trial)

Recruiting in Palo Alto (17 mi)

+18 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Terns, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.

Research Team

Eligibility Criteria

Adults with overweight or obesity are eligible for this trial. Specific health conditions and other criteria will be assessed to determine eligibility, but these details are not provided in the summary.

Inclusion Criteria

My BMI is between 27 and <50, with a weight-related health issue if it's 27-<30.

I am between 18 and 75 years old.

HbA1c < 6.5%

See 1 more

Exclusion Criteria

My obesity is caused by medication or a hormone disorder.

Lifetime history of suicide attempt

Have diabetes mellitus

See 1 more

Treatment Details

Interventions

TERN-601 (Other)

Trial OverviewThe study is testing TERN-601, an oral medication, against a placebo (a pill without active ingredients) to see if it's effective and safe for treating adults with overweight or obesity.

Participant Groups

5Treatment groups

Experimental Treatment

Placebo Group

Group I: TERN-601 Dose 4Experimental Treatment1 Intervention

Orally administered once daily.

Group II: TERN-601 Dose 3Experimental Treatment1 Intervention

Orally administered once daily.

Group III: TERN-601 Dose 2Experimental Treatment1 Intervention

Orally administered once daily.

Group IV: TERN-601 Dose 1Experimental Treatment1 Intervention

Orally administered once daily.